Compare BESS & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BESS | LEXX |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | Canada |
| Employees | 3 | 7 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 16.2M |
| IPO Year | N/A | N/A |
| Metric | BESS | LEXX |
|---|---|---|
| Price | $2.83 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 36.8K | ★ 180.1K |
| Earning Date | 03-31-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.06 | $0.46 |
| 52 Week High | $3.60 | $1.67 |
| Indicator | BESS | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 64.93 |
| Support Level | $2.50 | $0.98 |
| Resistance Level | $3.23 | $1.05 |
| Average True Range (ATR) | 0.38 | 0.10 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 58.60 | 83.33 |
Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.